FDA Approves Celltrion’s Denosumab Biosimilars for Bone Loss IndicationsByVictoria JohnsonMarch 4th 2025
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and OsteoporosisByMatthew J. Budoff, MD,Connor IapoceDecember 15th 2024
Denosumab Biosimilar Demonstrates Equivalent Efficacy, Safety in Phase 3 Trial ByVictoria JohnsonDecember 3rd 2024